ADReCS

Pharmaceutical Information

Drug Name	Prednisolone
Drug ID	BADD_D01831
Description	Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects.[A187463] Prednisolone was granted FDA approval on 21 June 1955.[L9431]
Indications and Usage	Prednisolone is indicated to treat endocrine, rheumatic, and hematologic disorders; collagen, dermatologic, ophthalmic, respiratory, and gastrointestinal diseases; allergic and edematous states; and other conditions like tuberculous meningitis.[L9542]
Marketing Status	approved; vet_approved
ATC Code	A01AC04; A07EA01; C05AA04; D07AA03; D07XA02; H02AB06; R01AD02; S01BA04; S01CB02; S02BA03; S03BA02
DrugBank ID	DB00860
KEGG ID	D00472
MeSH ID	D011239
PubChem ID	5755
TTD Drug ID	D0D1SG
NDC Product Code	38779-0150; 64958-0097; 82298-104; 67296-1656; 50383-042; 59651-491; 63187-466; 0527-5406; 65089-0038; 50090-0655; 57582-004; 62135-437; 73534-505; 49452-5980; 82298-105; 82298-106; 60592-911; 60722-3001; 51927-0234; 22552-0052
UNII	9PHQ9Y1OLM
Synonyms	Prednisolone \| Predate \| Predonine \| Di-Adreson-F \| Di Adreson F \| DiAdresonF

Chemical Information

Molecular Formula	C21H28O5
CAS Registry Number	50-24-8
SMILES	CC12CC(C3C(C1CCC2(C(=O)CO)O)CCC4=CC(=O)C=CC34C)O
Chemical Structure

ADRs Induced by Drug

*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..

ADR Term	ADReCS ID	ADR Frequency (FAERS)	ADR Severity Grade (FAERS)	ADR Severity Grade (CTCAE)
Photophobia	17.17.02.006; 06.01.01.004	0.000175%
Pica	19.09.01.009; 14.03.02.014	0.000035%		Not Available
Pleural effusion	22.05.02.002	0.000559%
Pleurisy	22.05.01.001	0.000122%		Not Available
Pneumonitis	22.01.01.006	0.000192%
Pneumothorax	22.05.02.003	0.000227%
Poikilocytosis	01.07.02.009	0.000035%		Not Available
Pollakiuria	20.02.02.007	0.000157%
Polydipsia	14.05.02.001; 05.03.03.002	0.000035%		Not Available
Polymyalgia rheumatica	15.06.01.001; 10.04.05.003	0.000122%		Not Available
Polyneuropathy	17.09.03.012	0.000122%		Not Available
Portal vein thrombosis	24.01.03.003; 09.01.06.007	0.000052%
Post herpetic neuralgia	17.02.07.014; 11.07.01.010	0.000035%		Not Available
Pre-eclampsia	20.01.08.002; 18.02.03.002; 24.08.07.002	0.000140%		Not Available
Premature baby	18.04.02.001	0.001084%		Not Available
Premature delivery	18.07.01.006	0.000426%
Premature labour	18.07.01.002	0.000087%		Not Available
Premature separation of placenta	24.07.03.019; 18.02.01.004	0.000035%		Not Available
Priapism	24.04.12.007; 21.03.01.005	0.000035%		Not Available
Prinzmetal angina	24.04.04.015; 02.02.02.019	0.000105%		Not Available
Proctalgia	07.03.02.001	0.000087%
Productive cough	22.02.03.005	0.000217%
Proteinuria	20.02.01.011	0.000280%
Psychomotor hyperactivity	19.11.02.003; 17.01.02.011	0.000329%		Not Available
Psychotic behaviour	19.03.01.003	0.000035%		Not Available
Pulmonary alveolar haemorrhage	24.07.01.015; 22.01.02.005	0.000122%		Not Available
Pulmonary congestion	24.03.08.001; 22.01.03.002; 02.05.02.002	0.000070%		Not Available
Pulmonary embolism	24.01.06.001; 22.06.02.001	0.000786%		Not Available
Pulmonary haemorrhage	24.07.01.016; 22.12.01.009	0.000140%
Pulmonary hypertension	24.08.03.002; 22.06.01.001	0.000122%

The 17th Page First Pre 17 18 19 20 21 Next Last Total 36 Pages